Evidence map›Paper›PMID 40457420›Full record

ArticlePediatric rheumatology online journal2025

Predictive factors of comorbid attention-deficit/hyperactivity disorder in early systemic autoimmune and auto-inflammatory disorders.

Briac Daniel, Eric Acquaviva, Brigitte Bader-Meunier, Alexandre Belot, Glory Dingulu, Cecile Dumaine, Albert Faye, Marie-Louise Frémond, Laura Lavialle, Ulrich Meinzer and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Briac DanielExcellence Centre for Autism & Neuro-developmental Disorders, Department of Child and Adolescent Psychiatry, APHP, Robert Debré Hospital, Université Paris-Cité, Boulevard Sérurier, Paris, France. briac.daniel@aphp.fr.
Eric AcquavivaExcellence Centre for Autism & Neuro-developmental Disorders, Department of Child and Adolescent Psychiatry, APHP, Robert Debré Hospital, Université Paris-Cité, Boulevard Sérurier, Paris, France.
Brigitte Bader-MeunierPediatric Hematology-Immunology and Rheumatology Department, AP-HP, and Reference centre for inflammatory Rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE), Hôpital Necker-Enfants Malades, Université Paris-Cité, Paris, France.
Alexandre BelotPediatric Nephrology, Rheumatology, Dermatology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 Bd Pinel, Lyon, Bron Cedex, 68677, France.
Glory DinguluGeneral Pediatrics, Infectious Disease and Internal Medicine Department, AP- HP, Hôpital Robert Debre, Université Paris-Cité, Paris, France.
Cecile DumaineGeneral Pediatrics, Infectious Disease and Internal Medicine Department, AP- HP, Hôpital Robert Debre, Université Paris-Cité, Paris, France.
Albert FayeGeneral Pediatrics, Infectious Disease and Internal Medicine Department, AP- HP, Hôpital Robert Debre, Université Paris-Cité, Paris, France.
Marie-Louise FrémondPediatric Hematology-Immunology and Rheumatology Department, AP-HP, and Reference centre for inflammatory Rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE), Hôpital Necker-Enfants Malades, Université Paris-Cité, Paris, France.
Laura LavialleExcellence Centre for Autism & Neuro-developmental Disorders, Department of Child and Adolescent Psychiatry, APHP, Robert Debré Hospital, Université Paris-Cité, Boulevard Sérurier, Paris, France.
Ulrich MeinzerGeneral Pediatrics, Infectious Disease and Internal Medicine Department, AP- HP, Hôpital Robert Debre, Université Paris-Cité, Paris, France.
Pierre QuartierPediatric Hematology-Immunology and Rheumatology Department, AP-HP, and Reference centre for inflammatory Rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE), Hôpital Necker-Enfants Malades, Université Paris-Cité, Paris, France.
Caroline VinitGeneral Pediatrics, Infectious Disease and Internal Medicine Department, AP- HP, Hôpital Robert Debre, Université Paris-Cité, Paris, France.
Richard DelormeExcellence Centre for Autism & Neuro-developmental Disorders, Department of Child and Adolescent Psychiatry, APHP, Robert Debré Hospital, Université Paris-Cité, Boulevard Sérurier, Paris, France.
Isabelle MelkiImagine Institute, Laboratory of Neurogenetics and Neuroinflammation, Inserm UMR 1163, Paris, France.
Pierre EllulExcellence Centre for Autism & Neuro-developmental Disorders, Department of Child and Adolescent Psychiatry, APHP, Robert Debré Hospital, Université Paris-Cité, Boulevard Sérurier, Paris, France. pierre.ellul@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe immune system is physiologically involved in brain development and homeostasis. Consequently, early immune-mediated events are known risk factors for neurodevelopmental disorders (NDD). We recently found that early systemic autoimmune and autoinflammatory disorders (ESAID) are associated with an increased risk of neurodevelopmental disorders due to the direct impact of inflammation on brain development. However not all ESAID patient will develop NDD. In this study, we aimed to better characterized the natural history of the NDD comorbidity and investigate the influence of others NDD risk factors in ESAID patients with ADHD (ESAID+/ADHD+; n = 14) compared to patient with ESAID without ADHD (ESAID+/ADHD-; n = 14) and patient with ADHD without ESAID (ESAID-/ADHD + = 35).

findingsWe did a case control study using a cohort of ESAID patients (ARTEMIS) and an ADHD cohort (Robert Debre) and found that the onset of ADHD in patients with ESAID is associated with global cognitive brain impairment that does not appear to be due to shared genetic risk factors, reinforcing the hypothesis of an immune-mediated mechanism. Regarding the etiopathogenesis of this comorbidity, we found that low birth weight, a known risk factor for NDD, contributes to the development of ADHD in ESAID patients.

conclusionsPediatricians, and in particular pediatric rheumatologists, need to be aware of the frequency of ADHD-related comorbidities in ESAID patients. They should therefore systematically look for NDD in ESAID patients, particularly in cases of low birth weight. Early detection and management of NDD is the only way to limit its impact on morbidity and life trajectory.

Indexed as

Attention Deficit Disorder with HyperactivityAutoimmune DiseasesInflammationAdolescentCase-Control StudiesChildChild, PreschoolComorbidityFemaleHumansMaleRisk FactorsChild and adolescent psychiatryNeurodevelopmentNeuroimmunology

Identifiers

PMID40457420
PMCPMC12128306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.